CARS1 (MGC:11246) as a Potential Drug Target and Biomarker (G833)

Target Name: CARS1

NCBI ID: G833

CARS1

CARS1 (MGC:11246) as a Potential Drug Target and Biomarker

Introduction

Cars1 (MGC:11246) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and various post-transcriptional modifications have piqued the interest of researchers, and studies have suggested that it plays a critical role in various cellular processes. In this article, we will explore the biology and potential therapeutic applications of Cars1, as well as its potential as a drug target and biomarker.

Structure and Function

Cars1 is a non-coding RNA molecule that contains 239 amino acid residues. It has a unique structure, with a 135 amino acid long terminal extension that is rich in conserved amino acid sequence. This extension is known as the \"Cars1-domain\" and is responsible for the molecule's unique stability and stability.

The Cars1-domain has several key features that make it an attractive drug target. Firstly, it has a high degree of homogeneity, which suggests that any potential drug that targets this region may be effective across different cell types. Secondly, the Cars1-domain has a strong positive charge, which can enhance the stability of RNA molecules and increase their resistance to degradation. This increased stability can potentially lead to longer expression levels and increased protein production.

In addition to its unique structure, Cars1 has several post-transcriptional modifications that have also caught the attention of researchers. These modifications include hypervariable non-coding RNAs (hnRNAs), microRNA (miRNA) cleavage, and post-transcriptional modification (PTM)- mediated stability enhancements. HnRNAs are self-cleavage RNAs that can interact with other RNAs and molecules, and miRNAs are small non-coding RNAs that can interact with hnRNAs to regulate their stability. PTM-mediated stability enhancements involve chemical modifications to the RNA molecule, such as methylation or acetylation, which can also impact its stability.

Potential therapeutic applications

The therapeutic potential applications of Cars1 are vast and varied. As a drug target, Cars1 has the potential to intervene in a wide range of cellular processes, including cell division, apoptosis, and signaling pathways. Its unique structure and post-transcriptional modifications make it an attractive target for small molecule inhibitors or RNA-based therapies.

In cancer, Cars1 has been shown to play a critical role in various cellular processes, including cell division, apoptosis, and angiogenesis. It has also been implicated in the development and progression of various types of cancer, including breast, lung, and colorectal cancers. . Therefore, targeting Cars1 with small molecules or RNA-based therapies has the potential to be a valuable cancer therapeutic.

As a biomarker, Cars1 has been shown to be a useful diagnostic tool for various diseases, including cancer. Its unique structure and post-transcriptional modifications make it a valuable target for diagnostic assays, such as qRT-PCR, RNA-seq, and mRNA -based assays. By detecting the expression and stability of Cars1, researchers can monitor the effectiveness of different therapeutic approaches and gain insights into the underlying biology of various diseases.

Conclusion

Cars1 is a unique non-coding RNA molecule that has captured the interest of researchers due to its unique structure and post-transcriptional modifications. Its potential as a drug target and biomarker makes it an attractive target for small molecule inhibitors or RNA-based therapies. Further research is needed to fully understand the biology and therapeutic applications of Cars1, and to develop safe and effective therapies that can be used to treat various diseases.

Protein Name: Cysteinyl-tRNA Synthetase 1

Functions: Catalyzes the ATP-dependent ligation of cysteine to tRNA(Cys)

The "CARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets